Transmolecular Imaging of Recurrent Prostate Carcinoma With Exploration of Genomic Markers Differences Between Local and Distant Recurrence
1. Patients must be 18 years of age or older.
2. Patients will have been originally diagnosed with localized (Stage T1c, T2, or T3 )
prostate carcinoma and have undergone what was considered definitive
non-prostatectomy therapy for localized disease.
3. In the case of cryotherapy, the procedure will have occurred at least one year in the
past. In the case of brachytherapy, or external beam radiation, treatment will have
occurred at least 2 years in the past to eliminate patients with so-called "PSA
4. Patient will have suspicion of recurrent prostate carcinoma as defined by: the
ASTRO-RTOG Phoenix criteria of nadir PSA +2, and absolute PSA ≥ 4.0 ng/ml.
5. Ability to lie still for PET scanning
6. Patients must be able to provide written informed consent.
1. Age less than 18.
2. Greater than T3 disease in past and/or treated with prostatectomy.
3. Less than 1 year since cryotherapy, or 2 years since brachytherapy or external beam
4. Does not meet above criteria of suspicious PSA elevation
5. Inability to lie still for PET scanning
6. Cannot provide written informed consent.
7. Bone scan findings characteristic for metastatic prostate carcinoma
8. Less than 1 month since any prior prostate biopsy (to decrease false positive uptake